To Evaluate Long- Term Safety and Efficacy of Luspatercept

Active, not recruitingOBSERVATIONAL

Enrollment

350

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

February 24, 2025

Study Completion Date

February 24, 2026

Conditions

Thalassemia Major

Interventions

DRUG

Luspatercept (ACE-536)

Trial Locations (1)

UniversityCagliari, OspPed Microcitemico, Cagliari, Cagliari

All Listed Sponsors

lead

Fondazione per la Ricerca sulle Anemie ed Emoglobinopatie in Italia

OTHER